FANCA and neoplasm: This can be explained by the frequent identification of several alterations that point towards identical treatment recommendations (e.g., BRCA mutation, ATM underexpression, FANCI, FANCA deletion for PARP inhibitors in the same patient) but were not always all named by both tumor boards.